Indo-National Limited announced its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. The Board of Directors, in a meeting held on February 4, 2026, approved these results. The company reported a standalone revenue from operations of ₹10,611.30 Lakhs for the quarter, a decrease from ₹12,163.30 Lakhs in the same period last year. The standalone net loss for the quarter was ₹661.95 Lakhs, compared to a profit of ₹63.18 Lakhs in the prior year's quarter. For the nine months ended December 31, 2025, the standalone revenue from operations stood at ₹34,462.22 Lakhs, with a net loss of ₹231.68 Lakhs. The consolidated revenue from operations for the quarter was ₹10,630.91 Lakhs, with a net loss of ₹1215.03 Lakhs. The consolidated nine-month revenue was ₹34,534.81 Lakhs, with a net loss of ₹1215.03 Lakhs. During the nine months, the company made significant investments, including ₹568.66 Lakhs for acquiring a 46.76% stake in Medcuore Medical Solutions Private Limited, making it a subsidiary. Additionally, ₹850 Lakhs was invested in Compulsory Convertible Preference Shares of Axial Aero Private Limited. The company also mentioned an ongoing application for the amalgamation of its wholly-owned subsidiary, Helios Strategic Systems Limited, with Indo-National Limited, with no objections reported so far. In a separate legal matter, the company is appealing a penalty imposed by the CCI related to cartelization, having deposited 10% of the penalty amount as per NCLAT's order. The New Labour Codes became effective, resulting in a past period employee benefit liability recognized for ₹86.00 Lakhs (standalone) and ₹87.00 Lakhs (consolidated).
